Table 3.
Univariate and multivariate analysis of DFS.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (≥65 vs <65 years) | 1.10 (0.72–1.70) | 0.65 | ||
| Gender (male vs female) | 1.20 (0.78–1.86) | 0.4 | ||
| Tumor location (head vs body/tail) | 2.06 (1.19–3.73) | <0.01 | 1.07 (0.29–2.79) | 0.1 |
| CEA (≥5 ng/mL vs <5 ng/mL) | 1.03 (0.65–1.64) | 0.89 | ||
| CA19–9 (≥100 U/mL vs <100 U/mL) | 1.13 (0.73–1.74) | 0.56 | ||
| Tumor size (≥20 mm vs <20 mm) | 1.85 (1.06–3.40) | 0.03 | 1.89 (1.15–3.31) | 0.03 |
| Peritoneal washing cytology (positive vs negative) | 1.87 (0.83–4.20) | 0.13 | ||
| Portal vein invasion (positive vs negative) | 1.03 (0.66–1.60) | 0.9 | ||
| Perineural invasion (positive vs negative) | 1.29 (0.81–2.05) | 0.28 | ||
| Lymph node metastasis (positive vs negative) | 1.73 (0.47–6.33) | 0.41 | ||
| UICC Stage IA/IB/IIA/IIB/IV | 1.95 (1.02–3.74) | 0.05 | ||
| EMT (mesenchymal vs epithelial) | 2.13 (1.35–3.42) | <0.01 | 2.23 (1.45–3.49) | <0.01 |
| LOXL2 expression | 1.89 (1.12–3.26) | 0.02 | 1.88 (1.16–3.15) | <0.01 |
Abbreviations, CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; EMT, epithelial-to-mesenchymal transition; LOXL2, lysyl oxidase-like protein 2; HR, hazard ratio; CI, confidence interval.